Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions
SC daratumumab deemed feasible for every multiple myeloma patient
Key clinical point: Subcutaneous (SC) daratumumab appears noninferior to intravenous (IV) daratumumab for patients with relapsed or refractory multiple myeloma.
Major finding: The overall response rate was 37.1% in patients who received daratumumab IV and 41.1% in those who received daratumumab SC (relative risk, 1.11; 95% confidence interval, 0.89-1.37; P less than .0001).
Study details: A phase 3 trial of 522 patients with relapsed/refractory multiple myeloma.
Disclosures: The trial was sponsored by Janssen Research & Development. Dr. Mateos reported relationships with Amgen, Celgene, Janssen-Cilag, and Takeda.
Citation:
Mateos MV et al. ASCO 2019, Abstract 8005.